About Novo Nordisk - ADR - Company Information, Overview, History and Profile
What does Novo Nordisk - ADR do?
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Novo Nordisk - ADR Management structure
All Gross Remunerations are in DKK
Mr. Lars Almblom Jorgensen
Executive Vice President, Quality, Regulatory and Business Development
57.1 M
2024
Gross Remuneration
Year
Mr. Karsten Munk Knudsen
Executive Vice President and Chief Financial Officer
26.8 M
2024
Gross Remuneration
Year
Mr. Maziar Mike Doustdar
Executive Vice President, International Operations
-
2024
Gross Remuneration
Year
Mr. Lars Fruergaard Jorgensen
Chief Executive Officer and President
-
2024
Gross Remuneration
Year
Mr. David Moore
Executive vice president, US Operations and Business Development
-
2024
Gross Remuneration
Year
Mr. Henrik Ehlers Wulff
Executive Vice President, Product Supply, Quality Assurance, Digital Data and Information Technology